Biomarkers /
PTK2B
Back to Biomarkers List
Associated Diseases
Overview
PTK2B is altered in 0.89% of all cancers with colon adenocarcinoma, lung adenocarcinoma, melanoma, glioblastoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in PTK2B are PTK2B Mutation (2.22%), PTK2B Loss (0.42%), PTK2B Fusion (0.03%), PTK2B I533M (0.07%), and PTK2B N883S (0.06%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.